MSACL 2018 EU Abstract

Self-Classified Topic Area(s): Proteomics

Combination of Stable Labelled Antibodies and LC-MS to Accurately Quantify Therapeutic Monoclonal Antibodies in the Clinical Laboratory

Dorothée LEBERT1, Guillaume PICARD1, Ravindra CHAUDHARI1, Aurélien MILLET2, Jérôme GUITTON2, Jean-François JOURDIL3, Françoise STANKE3.
1 Promise Advanced Proteomics, F-38040, Grenoble, France 2 Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Laboratoire de pharmaco-toxicologie, F-69495, Pierre Bénite, France. 3 CHU Grenoble, Laboratoire de pharmaco-toxicologie, F-38000, Grenoble, France

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Ravindra Chaudhari (Presenter)
PROMISE Advanced Proteomics

Relevant Financial Disclosures (within past 24 months)

Grant/Research Support PROMISE Advanced Proteomics

Salary PROMISE Advanced Proteomics

Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above.

Conflict mitigation IN PROCESS.

Abstract

We will present an innovative and generic approach involving the use of stable isotope labeled mAbs used as internal standards and LC-MS to allow accurate, sensitive and specific quantification, as required for therapeutic drug monitoring. Our approach was already tested and implemented with success in pharmacology laboratories on anti-TNF antibodies (Infliximab and Adalimumab) and was recently implemented for monitoring Cetuximab.